Lexeo Therapeutics reported interim Phase I/II data from its HEROIC-PKP2 program in arrhythmogenic cardiomyopathy, describing an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) versus baseline among high-dose patients. The company said the FDA is open to using NSVT frequency as a primary endpoint in a pivotal trial to support an accelerated approval pathway.